WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GALT

Based on 1 analyst offering 12 month price targets for Galectin Therapeutics Inc

Min Forecast
$11.00+182.05%
Avg Forecast
$11.00+182.05%
Max Forecast
$11.00+182.05%

Should I buy or sell GALT stock?

Based on 1 analyst offering ratings for Galectin Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GALT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates GALT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their GALT stock forecasts and price targets.

GALT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-23

1 of 1

Forecast return on equity

Is GALT forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is GALT forecast to generate an efficient return on assets?

Company
N/A
Industry
-4.33%

GALT earnings per share forecast

What is GALT's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.31
Avg 2 year Forecast
-$0.23

GALT revenue forecast

What is GALT's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$583.7M

GALT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GALT$3.90$11.00+182.05%Buy
ARCT$13.85$22.33+61.25%Strong Buy
IRD$4.76$12.67+166.11%Strong Buy
EDIT$2.58$4.50+74.42%Strong Buy
ZURA$4.04$21.00+419.80%Strong Buy
View Top Biotech Stocks

Galectin Therapeutics Stock Forecast FAQ

Is Galectin Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GALT) stock is to Buy GALT stock.

Out of 1 analyst, 0 (0%) are recommending GALT as a Strong Buy, 1 (100%) are recommending GALT as a Buy, 0 (0%) are recommending GALT as a Hold, 0 (0%) are recommending GALT as a Sell, and 0 (0%) are recommending GALT as a Strong Sell.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.

What is GALT's earnings growth forecast for 2026-2027?

(NASDAQ: GALT) Galectin Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.61%.

Galectin Therapeutics's earnings in 2026 is -$28,027,000.On average, 3 Wall Street analysts forecast GALT's earnings for 2026 to be -$30,859,991, with the lowest GALT earnings forecast at -$29,649,795, and the highest GALT earnings forecast at -$31,767,638.

In 2027, GALT is forecast to generate -$23,659,326 in earnings, with the lowest earnings forecast at -$22,731,510 and the highest earnings forecast at -$24,355,189.

What is GALT's revenue growth forecast for 2026-2028?

(NASDAQ: GALT) Galectin Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 43.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.28%.

Galectin Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast GALT's revenue for 2026 to be $0, with the lowest GALT revenue forecast at $0, and the highest GALT revenue forecast at $0. On average, 3 Wall Street analysts forecast GALT's revenue for 2027 to be $0, with the lowest GALT revenue forecast at $0, and the highest GALT revenue forecast at $0.

In 2028, GALT is forecast to generate $58,861,903,217 in revenue, with the lowest revenue forecast at $56,553,454,866 and the highest revenue forecast at $60,593,491,605.

What is GALT's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: GALT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -4.33%.

What is GALT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GALT price target, the average GALT price target is $11.00, with the highest GALT stock price forecast at $11.00 and the lowest GALT stock price forecast at $11.00.

The Wall Street analyst predicted that Galectin Therapeutics's share price could reach $11.00 by Jun 23, 2027. The average Galectin Therapeutics stock price prediction forecasts a potential upside of 182.05% from the current GALT share price of $3.90.

What is GALT's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: GALT) Galectin Therapeutics's current Earnings Per Share (EPS) is -$0.43. On average, analysts forecast that GALT's EPS will be -$0.31 for 2026, with the lowest EPS forecast at -$0.29, and the highest EPS forecast at -$0.32. In 2027, GALT's EPS is forecast to hit -$0.23 (min: -$0.23, max: -$0.24).

What is GALT's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: GALT) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.